Dengler Julius, Sturesson Bengt, Kools Djaya, Prestamburgo Domenico, Cher Daniel, van Eeckhoven Eddie, Erk Emanuel, Gasbarrini Alessandro, Pflugmacher Robert, Vajkoczy Peter
Charité-Universitaetsmedizin Berlin, Berlin, Germany.
Ängelholm Hospital, Ängelholm, Sweden.
Global Spine J. 2018 Aug;8(5):453-459. doi: 10.1177/2192568217733707. Epub 2017 Oct 5.
Secondary analysis of data from a randomized controlled trial.
To identify risk factors for continued opioid use after conservative management (CM) or minimally invasive surgical management (MISM) of low back pain (LBP) originating from the sacroiliac joint.
Patients were randomized either to CM (n = 49) or MISM (n = 52). We documented opioid use, pain intensity (visual analogue scale [VAS]), Oswestry Disability Index (ODI), and the Zung depression score (Zung Self-Rating Depression Scale) at baseline and at months 3 and 6 after treatment initiation.
Compared with opioid nonusers, opioid users at baseline had higher mean levels of disability (ODI 61.5, standard deviation [SD] 13.3 vs ODI 51.5, SD 12.8; < .01) and higher depression scores (Zung 48.5, SD 8.5, vs Zung 42.2, SD 7.2; < .01). At 6 months, opioid users had higher 6-month pain levels (VAS 60.4, SD 24.0, vs VAS 42.4, SD 28.2; < .01), higher disability scores (ODI 50.5, SD 16.2, vs ODI 32.7, SD 19.3; < .01) and higher depression scores (Zung 47.6, SD 8.0, vs Zung 38.8, SD 8.9; < .01). Risk factors for continued opioid use at 6 months were patient age (odds ratio [OR] for age = 0.91; = .02) and an increase in LBP (OR 1.08; = .02) in the CM group and a lack of improvement in depression scores (OR 1.12; = .03) in the MISM group.
In our patient cohort, the risk of continued opioid use in the treatment of LBP increased not only with pain intensity but also with levels of depression during the course of treatment.
对一项随机对照试验的数据进行二次分析。
确定源于骶髂关节的下腰痛(LBP)经保守治疗(CM)或微创外科治疗(MISM)后持续使用阿片类药物的风险因素。
将患者随机分为CM组(n = 49)或MISM组(n = 52)。我们记录了基线时以及治疗开始后3个月和6个月时的阿片类药物使用情况、疼痛强度(视觉模拟量表[VAS])、Oswestry功能障碍指数(ODI)和zung抑郁评分(zung自评抑郁量表)。
与未使用阿片类药物的患者相比,基线时使用阿片类药物的患者平均残疾水平更高(ODI 61.5,标准差[SD] 13.3 vs ODI 51.5,SD 12.8;P <.01),抑郁评分更高(zung 48.5,SD 8.5,vs zung 42.2,SD 7.2;P <.01)。在6个月时,使用阿片类药物的患者6个月时的疼痛水平更高(VAS 60.4,SD 24.0,vs VAS 42.4,SD 28.2;P <.01),残疾评分更高(ODI 50.5,SD 16.2,vs ODI 32.7,SD 19.3;P <.01),抑郁评分更高(zung 47.6,SD 8.0,vs zung 38.8,SD 8.9;P <.01)。CM组6个月时持续使用阿片类药物的风险因素是患者年龄(年龄的优势比[OR] = 0.91;P =.02)和LBP增加(OR 1.08;P =.02),MISM组是抑郁评分没有改善(OR 1.12;P =.03)。
在我们的患者队列中,治疗LBP时持续使用阿片类药物的风险不仅随着疼痛强度增加,而且在治疗过程中随着抑郁水平增加。